Basal cell carcinoma left in place does not stay the same size forever. It continues to grow, slowly destroying the tissue around it, and given enough time it can eat through skin, muscle, cartilage, and even bone. The tumor rarely kills, but “rarely” and “never” are not the same thing, and the damage it causes along the way can be devastating even when it doesn’t spread to distant organs. What makes BCC deceptive is its pace: it grows slowly enough that people rationalize waiting, but steadily enough that waiting always costs something.
How Fast an Untreated BCC Actually Grows
A systematic review pooling data from multiple studies found that the average BCC grows along its longest axis at about 0.7 mm per month.1PubMed Central. Growth rate of basal cell carcinoma: a meta-analysis and systematic review That sounds trivial, and in a single month it is. But over a year it adds up to roughly 8 mm of new tumor spread, and over several years it becomes a substantially larger lesion that has had time to push into deeper structures. That average also obscures significant variation. Some BCCs barely budge for years. Others, particularly the aggressive subtypes, grow considerably faster and invade more deeply than their surface dimensions suggest.
The slow pace is partly why so many people put off treatment. A study looking at reasons for delayed care found that denial was the most common factor, accounting for about 71% of cases. People thought the spot would go away on its own, didn’t think it was important, were too busy, or were afraid of what a doctor might tell them. Only about 10% of delays were caused by difficulty getting an appointment.2PubMed. Delayed treatment and continued growth of nonmelanoma skin cancer In low- and middle-income countries, barriers also include a shortage of dermatologists, the cost of healthcare, stigma around a cancer diagnosis, and reliance on non-medical therapies.3PubMed Central. Barriers to Skin Cancer Diagnosis and Treatment in Low- and Middle-Income Countries and Solutions: A Literature Review
What “Local Destruction” Really Means
BCC almost never metastasizes, and that reputation for being “harmless” leads people to underestimate what it can do to the area where it sits. The tumor doesn’t push tissue aside the way a benign growth would. It infiltrates and replaces normal tissue. On the face, that means it can work its way into the eyelids, the nose, the ear canal, or the lips. One case report described an 80-year-old man whose neglected facial BCC had consumed his left eye and orbit, his left nostril, and much of his left cheek by the time he sought care.4Gomal Journal of Medical Sciences. ADVANCED STAGE OF FACIAL BASAL CELL CARCINOMA That kind of outcome is not typical, but it is not as rare as you might hope. It happens when people ignore a slowly growing sore for years or decades.
The head and neck are where roughly 80% of BCCs appear, and these locations put vital structures at risk. A tumor near the eye can destroy vision not by invading the eyeball itself but by eroding the bony orbit or damaging the muscles that move the eye. A BCC on the nose can eat through cartilage and leave a hole. On the scalp, neglected tumors have been documented growing large enough to invade the skull bone itself.5PubMed Central. Neglected giant scalp Basal cell carcinoma
When BCC Reaches Bone
Bone invasion is one of the more alarming endpoints of untreated BCC. A review of more than 10,000 patients treated for facial BCC at a single center over 30 years identified eight patients whose tumors had invaded the facial bones. The average tumor diameter in that group was about 39 mm, and the average age at diagnosis was 75.6PubMed Central. Basal Cell Carcinoma Infiltrating the Facial Bones—Is It Really a Thing of the Past? Personal Experience over 30 Years and a Review of the Literature Eight cases in 10,000 sounds low, but those eight patients faced far more complex surgery and far worse outcomes than they would have with earlier treatment.
Not all BCC subtypes carry the same risk for deep invasion. A study of infiltrative BCCs of the head found that bone-invading tumors were most commonly classified as nodular or nodular-infiltrating types, and every morphoeic (also called morpheaform) variant in the study had invaded bone in the surrounding region.7PubMed Central. Infiltrative Basal Cell Carcinoma of the Head: Factors Influencing Bone Invasion and Surgical Outcomes This matters because morpheaform BCCs are the subtype most likely to be underestimated clinically. They look like a flat, whitish scar on the skin rather than the classic pearly bump, which makes them easy to miss and easy to dismiss.
Aggressive Subtypes and Why They Matter
Most BCCs are the nodular type, which is the classic slow-growing, pearly-bordered bump. But a meaningful minority are aggressive-growth subtypes. In one large study of biopsy specimens, roughly one in five BCCs fell into an aggressive category: about 13% morpheaform, nearly 6% infiltrative, and close to 2% micronodular.8Journal of the American Academy of Dermatology. Increased proportion of aggressive-growth basal cell carcinoma in the Veterans Affairs population of Palo Alto, California
The practical problem is that aggressive subtypes are harder to see with the naked eye and harder to clear surgically. A morpheaform BCC doesn’t form a neat border. It sends finger-like extensions of tumor cells outward through surrounding tissue, which means the actual margins of the cancer extend well beyond what’s visible on the surface. If you leave such a tumor alone, it doesn’t just grow as a lump. It threads itself through tissue in unpredictable directions. That makes eventual treatment more destructive and more prone to leaving residual tumor behind.
Nerve Invasion and Its Consequences
One of the less-discussed risks of leaving a BCC in place is perineural invasion, where tumor cells grow along and into nerves. A study examining BCC specimens found perineural invasion in about 20% of patients, with another 31% showing chronic inflammation around nerves that may signal early nerve involvement.9PubMed Central. Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion-Findings and Perspectives Perineural invasion was associated with larger tumors, deeper growth, and higher-risk histological types.
When a BCC invades nerves, the consequences go beyond the tumor itself. You can develop numbness, tingling, pain, or muscle weakness in the area served by the affected nerve. On the face, that can mean drooping of the eyelid or lip, loss of sensation in the cheek or forehead, or chronic facial pain. These symptoms sometimes appear well before a tumor looks advanced on the surface, since the cancer can track along a nerve trunk for some distance while the visible lesion remains deceptively small. Perineural invasion also makes surgical cure harder, because the surgeon must follow the nerve to ensure all tumor cells are cleared.
Metastasis Is Rare but Not Impossible
The standard reassurance about BCC is that it almost never spreads to distant parts of the body. That’s true. Estimates of metastasis range from roughly 0.003% to 0.55% of all BCC cases, depending on the study.10PubMed Central. Metastatic basal cell carcinoma with atypical pattern of spread The primary tumor in metastatic cases almost always originates in the head and neck region, in roughly 85% of cases.11PubMed Central. Metastatic Basal cell carcinoma: a biological continuum of Basal cell carcinoma?
A major risk factor for metastatic BCC is exactly what this article is about: neglecting a primary lesion for many years.10PubMed Central. Metastatic basal cell carcinoma with atypical pattern of spread When BCC does spread, it typically starts through the lymphatic system, reaching nearby lymph nodes first, and then can transition to blood-borne spread reaching the lungs, bones, or other sites. The prognosis for metastatic BCC is poor. This is a cancer that is almost universally curable when caught early but becomes extremely difficult to manage once it has spread beyond its original site.
The rarity of metastasis shouldn’t lull anyone into complacency. It’s rare across the full population of BCCs, most of which are detected and treated relatively early. Among the subset of BCCs that go untreated for many years and grow large, the metastatic risk is meaningfully higher than those population-wide statistics suggest.
Giant Neglected Tumors
Case reports of giant BCCs make up a small but sobering corner of the medical literature. These are tumors that patients have ignored for years, sometimes a decade or more, until the lesion has grown to an enormous size. A giant BCC is generally defined as one measuring 5 cm or more, and some reported cases have been far larger than that. These tumors invade deep tissue, sometimes down to and through bone, and they create enormous challenges for both treatment and reconstruction.5PubMed Central. Neglected giant scalp Basal cell carcinoma
When a tumor reaches this stage, simply cutting it out may leave a wound that can’t be closed with the surrounding tissue. Large regional or free muscle flaps are often needed, with the latissimus dorsi (a large back muscle) being one of the most commonly used because of its size and reliable blood supply.12Plastic and Reconstructive Surgery – Global Open. Denying the Obvious: Four Extreme Cases of Neglected Tumors Postoperative radiation therapy may also be required to reduce the risk of recurrence. What would have been a 30-minute outpatient procedure years earlier becomes a major surgery with hospitalization, long recovery, and the possibility of permanent disfigurement.
Can BCC Ever Go Away on Its Own?
Spontaneous regression of BCC has been documented, but it is rare. The immune system can occasionally mount a response against a BCC, and immune cells infiltrating the tumor may destroy it without treatment. Rates of BCC are higher in people with suppressed immune systems, which indirectly supports the idea that immune surveillance plays some role in controlling these tumors.13PubMed Central. The Immune Microenvironment in Basal Cell Carcinoma Detailed analysis of regressing BCCs shows that certain types of immune cells flood the tumor, but the process is not well understood and cannot be predicted or relied upon.14PubMed Central. Basal cell carcinoma with spontaneous regression: a case report and immunohistochemical study
The key word is “rare.” Spontaneous regression has been observed often enough to merit case reports and immunological study, but it is absolutely not common enough to justify waiting and hoping. For every BCC that regresses, many thousands do not. Betting on spontaneous resolution is like refusing to fix a roof leak because you heard about a house where the leak sealed itself.
When Doctors Do Recommend Watching Instead of Cutting
There is one situation where leaving a BCC in place is a deliberate, medically supervised strategy. For older patients with limited life expectancy and low-risk tumor subtypes, watchful waiting can be a reasonable choice. An observational study of 280 BCCs in 89 patients concluded that watchful waiting may be appropriate for patients with limited life expectancy who have asymptomatic nodular or superficial BCCs.15PubMed Central. Evaluation of Watchful Waiting and Tumor Behavior in Patients With Basal Cell Carcinoma: An Observational Cohort Study of 280 Basal Cell Carcinomas in 89 Patients A study examining patient experiences with this approach found that active surveillance was valued by older patients and those with cumulative treatment burden from having had many BCCs removed over the years.16PubMed. Active surveillance for basal cell carcinoma: experiences of patients and proxies
This approach does not mean ignoring the tumor. It means checking it regularly, typically every few months, with a clear plan to intervene if the BCC starts growing faster, develops symptoms like bleeding or pain, or moves toward a high-risk anatomical site. Watchful waiting is for specific, carefully selected situations. It is not a license for anyone with a BCC to skip treatment, and it is not what most people mean when they wonder what happens if they don’t get their BCC removed. Most people asking that question are in a position where treatment is straightforward and the tumor should come out.
What Happens When Surgery Is No Longer an Option
For the small fraction of BCCs that reach a stage where surgery would cause unacceptable damage or simply can’t remove all the tumor, medical treatment exists but is far less ideal than early surgery. The two approved hedgehog pathway inhibitors, vismodegib and sonidegib, can shrink advanced BCCs that are not candidates for surgery.17PubMed. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma These drugs block a signaling pathway that drives BCC growth and can produce meaningful tumor shrinkage, but they come with significant side effects including muscle spasms, hair loss, taste disturbances, and fatigue.
If a patient develops resistance to hedgehog inhibitors or can’t tolerate them, immunotherapy with checkpoint inhibitors is an emerging option, though experts generally recommend keeping patients on hedgehog inhibitors first and reserving immunotherapy for those who have run out of other choices.18PubMed. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors
None of these treatments are as simple or effective as catching and removing a small BCC early. They represent the fallback plan for tumors that have been allowed to reach a stage where straightforward treatment is no longer possible.
The Financial Cost of Delay
Early BCC removal is one of the least expensive procedures in dermatology. A standard excision can often be done in an office visit. The cost equation changes dramatically for advanced disease. Vismodegib, typically taken for about 10 months, can cost upward of $139,000. Sonidegib over a typical 11-month course runs roughly $144,000. And if a patient needs the immunotherapy drug cemiplimab, administered as infusions every three weeks, the average cost before benefit is seen reaches about $185,000.19PubMed Central. Recommendations for Cost-Conscious Treatment of Basal Cell Carcinoma
These figures don’t include the cost of complex reconstructive surgery, hospital stays, radiation therapy, or the extended follow-up that advanced disease demands. A patient who has extensive tissue reconstruction with a free muscle flap faces weeks of recovery, possible complications at both the donor and recipient sites, and often the need for further surgeries to refine the result. The financial and personal cost of treating an advanced BCC dwarfs the inconvenience of having a small one removed early.
The Psychological and Quality-of-Life Toll
BCC on visible areas like the face and neck carries a measurable psychological burden, and this burden is worse when the tumor is advanced. Research on patients receiving treatment for advanced BCC found that those with tumors in visible locations reported higher impacts on quality of life than those with tumors on the trunk or limbs.20SpringerLink (Dermatology and Therapy). Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test That effect moderated after treatment, but for patients who have delayed care, the period of living with a visibly growing lesion on the face can cause significant social withdrawal, anxiety, and shame.
Beyond the tumor itself, the reconstruction required after extensive surgery can leave lasting cosmetic changes. Losing a portion of the nose, an ear, or the tissue around an eye is not something that can be fully restored. Modern surgical techniques are remarkably good, but “remarkably good reconstruction” and “looking like nothing happened” are two very different things. The emotional weight of facial disfigurement is real and well-documented, and it stacks on top of the medical burden of the disease itself.
Alternatives to Traditional Surgery for Early BCC
If what’s holding someone back from treatment is fear of surgery specifically, it’s worth knowing that not every BCC requires a scalpel. Depending on the tumor’s type, size, and location, treatment options for early-stage BCC include cryosurgery (freezing), curettage (scraping), photodynamic therapy, topical medications like 5-fluorouracil or imiquimod, and radiation.21PubMed Central. Nonsurgical Options for the Treatment of Basal Cell Carcinoma These approaches work best for superficial or small nodular BCCs in low-risk locations. They are generally less effective than surgery for aggressive subtypes or tumors in high-risk areas like the nose, eye, or ear, but they offer real alternatives for the many people whose BCCs are small and straightforward.
The window for these less invasive options closes as a BCC grows. A tumor that could have been treated with a topical cream at 5 mm may require Mohs surgery at 15 mm and a complex flap reconstruction at 40 mm. Every month of waiting shrinks the menu of treatment choices and pushes the patient toward options that are more invasive, more expensive, and more likely to leave a scar.